Shanghai Xinzhi BioMed Co., Ltd.

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
A Clinical Study to Evaluate the Safety, and Tolerability of BBM-P002 in the Treatment of Parkinson's Disease	PD	Recruiting	Phase 1	2026-08-04	NCT07195825
Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, X-linked disease, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia B, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder	Active, not recruiting	Phase 2 / Phase 3	2026-04-01	NCT05203679
Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder	Recruiting	Phase 2 / Phase 3	2026-03-17	NCT06111638
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.	Duchenne muscular dystrophy	Recruiting	Phase 1 / Phase 2	2025-12-04	NCT07058662

Clinical trials